

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:	

Iloprost

Initial application — PAH monotherapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

Prerequisites (tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)																															
and	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications																														
and	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV																														
and	<table border="0"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)</td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures</td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Iloprost is to be used as PAH monotherapy</td><td></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)	and	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type	or	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease	or	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures	and	<table border="0"><tr><td><input type="checkbox"/> Iloprost is to be used as PAH monotherapy</td><td></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table></td></tr></table>	<input type="checkbox"/> Iloprost is to be used as PAH monotherapy		and	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)		or	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation																															
and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)																														
and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg																														
and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)																														
and	<table border="0"><tr><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH		or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																								
<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH																															
or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**																														
or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type																														
or	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease																														
or	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures																														
and	<table border="0"><tr><td><input type="checkbox"/> Iloprost is to be used as PAH monotherapy</td><td></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table></td></tr></table>	<input type="checkbox"/> Iloprost is to be used as PAH monotherapy		and	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)		or	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists																						
<input type="checkbox"/> Iloprost is to be used as PAH monotherapy																															
and	<table border="0"><tr><td><input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists</td></tr></table>	<input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)		or	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists																										
<input type="checkbox"/> Patient has experienced intolerable side effects on sildenafil and both the funded endothelin receptor antagonists (i.e. both bosentan and ambrisentan)																															
or	<input type="checkbox"/> Patient has an absolute contraindication to sildenafil and an absolute or relative contraindication to endothelin receptor antagonists																														

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:

Iloprost - *continued*

Initial application — PAH dual therapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)															
and	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications														
and	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV														
and	<table border="0"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)</td></tr><tr><td>or</td><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)	or	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH	or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation															
and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)														
and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg														
and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)														
or	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH														
or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**														
or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type														
or	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease														
or	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures														
and	<table border="0"><tr><td><input type="checkbox"/> Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist</td><td></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist</td></tr></table></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy</td></tr></table></td></tr></table>	<input type="checkbox"/> Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist		and	<table border="0"><tr><td><input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist</td></tr></table>	<input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil		or	<input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist	and	<table border="0"><tr><td><input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy</td></tr></table>	<input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy
<input type="checkbox"/> Iloprost is to be used as PAH dual therapy with either sildenafil or an endothelin receptor antagonist															
and	<table border="0"><tr><td><input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist</td></tr></table>	<input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil		or	<input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist										
<input type="checkbox"/> Patient has an absolute contraindication to or has experienced intolerable side effects on sildenafil															
or	<input type="checkbox"/> Patient has an absolute or relative contraindication to or experienced intolerable side effects with a funded endothelin receptor antagonist														
and	<table border="0"><tr><td><input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy</td></tr></table>	<input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**		or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy										
<input type="checkbox"/> Patient has tried a PAH monotherapy for at least three months and remains in an unacceptable risk category according to a validated risk stratification tool**															
or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class III or IV, and in the opinion of the treating clinician would benefit from initial dual therapy														

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:

Iloprost - *continued*

Initial application — PAH triple therapy

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

<input type="checkbox"/> Patient has pulmonary arterial hypertension (PAH)															
and	<input type="checkbox"/> PAH is in Group 1, 4 or 5 of the WHO (Venice 2003) clinical classifications														
and	<input type="checkbox"/> PAH is in New York Heart Association/World Health Organization (NYHA/WHO) functional class II, III or IV														
and	<table border="0"><tr><td><input type="checkbox"/> PAH has been confirmed by right heart catheterisation</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg</td></tr><tr><td>and</td><td><input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm⁻⁵)</td></tr><tr><td>or</td><td><input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**</td></tr><tr><td>or</td><td><input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type</td></tr></table>	<input type="checkbox"/> PAH has been confirmed by right heart catheterisation		and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)	and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg	and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)	or	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH	or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**	or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type
<input type="checkbox"/> PAH has been confirmed by right heart catheterisation															
and	<input type="checkbox"/> A mean pulmonary artery pressure (PAPm) greater than 20 mmHg (unless peri Fontan repair)														
and	<input type="checkbox"/> A pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg														
and	<input type="checkbox"/> A pulmonary vascular resistance greater than 2 Wood Units or greater than 160 International Units (dyn s cm ⁻⁵)														
or	<input type="checkbox"/> PAH has been demonstrated to be non-responsive in vasoreactivity assessment using iloprost or nitric oxide, as defined in the 2022 ECS/ERS Guidelines for PAH														
or	<input type="checkbox"/> Patient has not experienced an acceptable response to calcium antagonist treatment, according to a validated risk stratification tool**														
or	<input type="checkbox"/> Patient has PAH other than idiopathic / heritable or drug-associated type														
or	<input type="checkbox"/> Patient is a child with PAH secondary to congenital heart disease or PAH due to idiopathic, congenital or developmental lung disorders including chronic neonatal lung disease														
or	<input type="checkbox"/> Patient has palliated single ventricle congenital heart disease and elevated pulmonary pressures or a major complication of the Fontan circulation requiring the minimising of pulmonary/venous filling pressures														
and	<table border="0"><tr><td><input type="checkbox"/> Iloprost is to be used as PAH triple therapy</td><td></td></tr><tr><td>and</td><td><table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td></tr><tr><td>or</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table></td></tr></table>	<input type="checkbox"/> Iloprost is to be used as PAH triple therapy		and	<table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td></tr><tr><td>or</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table>	<input type="checkbox"/> Patient is on the lung transplant list		or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV	or	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**		and	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario
<input type="checkbox"/> Iloprost is to be used as PAH triple therapy															
and	<table border="0"><tr><td><input type="checkbox"/> Patient is on the lung transplant list</td><td></td></tr><tr><td>or</td><td><input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV</td></tr><tr><td>or</td><td><table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table></td></tr></table>	<input type="checkbox"/> Patient is on the lung transplant list		or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV	or	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**		and	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario				
<input type="checkbox"/> Patient is on the lung transplant list															
or	<input type="checkbox"/> Patient is presenting in NYHA/WHO functional class IV														
or	<table border="0"><tr><td><input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**</td><td></td></tr><tr><td>and</td><td><input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario</td></tr></table>	<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**		and	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario										
<input type="checkbox"/> Patient has tried PAH dual therapy for at least three months and has not experienced an acceptable response to treatment according to a validated risk stratification tool**															
and	<input type="checkbox"/> Patient does not have major life-threatening comorbidities and triple therapy is not being used in a palliative scenario														

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....
Fax Number:	Fax Number:	

Iloprost - *continued*

Renewal

Current approval Number (if known):.....

Applications only from a respiratory specialist, cardiologist, rheumatologist or any relevant practitioner on the recommendation of a respiratory specialist, cardiologist or rheumatologist. Approvals valid for 2 years.

Prerequisites(tick box where appropriate)

Patient is continuing to derive benefit from iloprost treatment according to a validated PAH risk stratification tool**

Note: ** the requirement to use a validated risk stratification tool to determine insufficient response applies to adults. Determining insufficient response in children does not require use of a validated PAH risk stratification tool, where currently no such validated tools exist for PAH risk stratification in children.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz